Perceived Social Support and Medication Dose Interruption Among Pulmonary Tuberculosis Patients in Western India: A Cross-Sectional Study.

Introduction Despite efforts, tuberculosis (TB) remains a major public health problem in developing countries, and India alone accounts for most of the global TB cases. Although the treatment for TB is highly successful, a significant number of TB patients in India do not complete their assigned treatment. Social support has a key influence on medication adherence for chronic illnesses like diabetes, asthma, HIV, hypertension, cardiovascular diseases, and TB.

The Rice Online Expression Profiles Array Database Version 2 (ROADv2): An Interactive Atlas for Rice Functional Genomics.

The Rice Online expression profiles Array Database version 2 (ROADv2; https://roadv2.khu.ac.

Impact of Dexmedetomidine-Based Opioid-Sparing Anesthesia on Opioid Use After Minimally Invasive Repair of Pectus Excavatum: A Prospective Randomized Controlled Trial.

Opioid-sparing anesthesia (OSA) using dexmedetomidine has gained attention as an alternative to opioid-based anesthesia (OBA) due to its potential to reduce opioid consumption and the associated side effects. This study aimed to investigate the effect of dexmedetomidine-based OSA on postoperative pain intensity, opioid consumption, and recovery outcomes in patients undergoing a minimally invasive repair of pectus excavatum. Eighty-four patients undergoing a minimally invasive repair of pectus excavatum were randomized to either the OSA group, receiving dexmedetomidine, or the OBA group, receiving remifentanil.

Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphoma: A Cell Therapy Consortium Real-World Analysis.

Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR T cell therapy approved for the treatment of relapsed/refractory large B-cell lymphoma (LBCL). We present a multicenter retrospective study evaluating safety, efficacy, and resource utilization of liso-cel in the standard-of-care setting. Patients received commercial liso-cel at 7 US medical centers and patient selection, toxicity management, and disease assessment followed institutional practices.